Stock 7427 GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Great Novel Therapeutics Biotech & Medicals

Equities

7427

TW0007427007

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
48.5 TWD -1.32% Intraday chart for Great Novel Therapeutics Biotech & Medicals -6.73% -27.40%
Mar. 20 Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Great Novel Therapeutics Biotech & Medicals(TPEX:7427) added to S&P Global BMI Index CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 935.7 1,823 2,562
Enterprise Value (EV) 1 810.6 1,576 2,099
P/E ratio -24.4 x -27.2 x -39.3 x
Yield - - -
Capitalization / Revenue 1,485 x 3,376 x 528 x
EV / Revenue 1,287 x 2,918 x 433 x
EV / EBITDA -23.1 x -28.3 x -32.9 x
EV / FCF -27,453,279 x -28,713,004 x -43,210,089 x
FCF Yield -0% -0% -0%
Price to Book 4.49 x 5.1 x 4.15 x
Nbr of stocks (in thousands) 22,575 29,030 38,357
Reference price 2 41.45 62.80 66.80
Announcement Date 3/31/22 4/14/23 4/2/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2.857 0.088 - 0.63 0.54 4.85
EBITDA 1 -36.02 -29.43 -28.9 -35.08 -55.68 -63.76
EBIT 1 -37.13 -30.46 -29.89 -36.52 -57.44 -66.36
Operating Margin -1,299.68% -34,610.23% - -5,796.98% -10,636.67% -1,368.31%
Earnings before Tax (EBT) 1 -35.78 -29.88 -31.26 -35.86 -55.78 -61.54
Net income 1 -35.78 -29.88 -31.26 -35.86 -55.78 -61.54
Net margin -1,252.36% -33,948.86% - -5,691.59% -10,329.44% -1,268.87%
EPS 2 -3.244 -2.203 -1.973 -1.701 -2.310 -1.700
Free Cash Flow - -38.85 -39.85 -29.53 -54.87 -48.59
FCF margin - -44,146.16% - -4,686.92% -10,161.25% -1,001.81%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/25/20 11/25/20 3/29/21 3/31/22 4/14/23 4/2/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 62.1 38.4 67 125 248 463
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -38.8 -39.8 -29.5 -54.9 -48.6
ROE (net income / shareholders' equity) - -44.1% -33.3% -21.8% -19.6% -12.6%
ROA (Net income/ Total Assets) - -24% -17.7% -12.8% -11.9% -8.15%
Assets 1 - 124.6 177 279.5 468.3 755
Book Value Per Share 2 6.210 4.700 6.490 9.230 12.30 16.10
Cash Flow per Share 2 4.230 1.740 3.610 2.780 3.790 4.680
Capex 1 0.18 - 0.02 0.04 0.05 2.93
Capex / Sales 6.37% - - 5.87% 8.33% 60.31%
Announcement Date 11/25/20 11/25/20 3/29/21 3/31/22 4/14/23 4/2/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS Stock Great Novel Therapeutics Biotech & Medicals
-27.40% 57.92M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 7427 Stock
  4. Financials Great Novel Therapeutics Biotech & Medicals